Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at HC Wainwright reduced their Q4 2024 earnings estimates for Eledon Pharmaceuticals in a research report issued on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now expects that the company will earn ($0.32) per share for the quarter, down from their previous estimate of ($0.22). HC Wainwright has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals' FY2025 earnings at ($0.91) EPS.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02).
Eledon Pharmaceuticals Trading Down 1.5 %
ELDN traded down $0.06 during trading on Friday, hitting $4.01. 175,185 shares of the company's stock were exchanged, compared to its average volume of 197,909. Eledon Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $5.54. The stock has a 50 day moving average price of $3.37 and a 200 day moving average price of $2.93. The firm has a market cap of $159.04 million, a P/E ratio of -2.02 and a beta of 0.76.
Institutional Trading of Eledon Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of ELDN. Clarity Capital Partners LLC bought a new position in Eledon Pharmaceuticals in the 3rd quarter valued at about $29,000. Dimensional Fund Advisors LP acquired a new position in shares of Eledon Pharmaceuticals in the second quarter worth about $80,000. Marco Investment Management LLC lifted its position in shares of Eledon Pharmaceuticals by 22.3% in the second quarter. Marco Investment Management LLC now owns 30,344 shares of the company's stock worth $80,000 after purchasing an additional 5,535 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Eledon Pharmaceuticals by 57.1% in the second quarter. Renaissance Technologies LLC now owns 136,773 shares of the company's stock worth $361,000 after purchasing an additional 49,704 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Eledon Pharmaceuticals by 9.7% in the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company's stock worth $942,000 after purchasing an additional 33,569 shares in the last quarter. 56.77% of the stock is owned by institutional investors and hedge funds.
About Eledon Pharmaceuticals
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
